Table 3. Cardiovascular Assessments for Patients Receiving TKIs for CML-CP.

Assessment	Imatinib	Dasatinib	Nilotinib	Bosutinib	Ponatinib
Baseline
Clinical CV assessment	Y	Y	Y	Y	Y
Blood pressure	Y	Y	Y	Y	Y
Fasting glucose	AI	AI	Y	AI	Y
Fasting lipids	AI	AI	Y	AI	Y
Electrocardiogram	Y	Y	Y	Y	Y
Echocardiogram	AI	AI	AI	AI	AI
Ankle-brachial index	AI	AI	AI	AI	AI
1-month follow-up
Clinical CV assessment	AI	Y	Y	AI	Y
Blood pressure	AI	AI	AI	AI	Y
3- to 6-month follow-upa
Clinical CV assessment	Y	Y	Y	Y	Y
Blood pressure	AI	AI	Y	AI	Y
Fasting glucose	AI	AI	Y	AI	AI
Fasting lipids	AI	AI	Y	AI	Y
Electrocardiogram	AI	AI	Y	AI	Y
Echocardiogram	AI	AI	AI	AI	AI
Ankle-brachial index	AI	AI	AI	AI	AI

Note. Assessments should be performed more frequently in patients with high cardiovascular risk or if clinically indicated. AI = as indicated; CV = cardiovascular; Y = yes. Table adapted with permission from Barber et al. (2017)

^aFollow-ups should continue every 3–6 months and at least yearly for patients in stable condition.